Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1981 2
1982 2
1983 1
1984 1
1986 1
1987 1
1989 1
1993 1
1994 1
1998 3
2000 1
2004 2
2005 1
2006 1
2008 2
2010 2
2012 2
2013 1
2014 3
2015 3
2016 2
2017 1
2018 2
2019 5
2020 6
2021 2
2022 4
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, Colombo A, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Carinelli S, Provencher D, Hanzen C, Lutgens LCHW, Smit VTHBM, Singh N, Do V, D'Amico R, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC study group. de Boer SM, et al. Among authors: hanzen c. Lancet Oncol. 2018 Mar;19(3):295-309. doi: 10.1016/S1470-2045(18)30079-2. Epub 2018 Feb 12. Lancet Oncol. 2018. PMID: 29449189 Free PMC article. Clinical Trial.
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial.
de Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, Ottevanger PB, Ledermann JA, Khaw P, D'Amico R, Fyles A, Baron MH, Jürgenliemk-Schulz IM, Kitchener HC, Nijman HW, Wilson G, Brooks S, Gribaudo S, Provencher D, Hanzen C, Kruitwagen RF, Smit VTHBM, Singh N, Do V, Lissoni A, Nout RA, Feeney A, Verhoeven-Adema KW, Putter H, Creutzberg CL; PORTEC Study Group. de Boer SM, et al. Among authors: hanzen c. Lancet Oncol. 2019 Sep;20(9):1273-1285. doi: 10.1016/S1470-2045(19)30395-X. Epub 2019 Jul 22. Lancet Oncol. 2019. PMID: 31345626 Free PMC article. Clinical Trial.
Target volume delineation for radiotherapy of meningiomas: an ANOCEF consensus guideline.
Martz N, Salleron J, Dhermain F, Vogin G, Daisne JF, Mouttet-Audouard R, Tanguy R, Noel G, Peyre M, Lecouillard I, Jacob J, Attal J, Charissoux M, Veresezan O, Hanzen C, Huchet A, Latorzeff I, Coutte A, Doyen J, Stefan D, Feuvret L, Garcia GCTE, Royer P. Martz N, et al. Among authors: hanzen c. Radiat Oncol. 2023 Jul 5;18(1):113. doi: 10.1186/s13014-023-02300-w. Radiat Oncol. 2023. PMID: 37408055 Free PMC article. Review.
When is a cow in estrus? Clinical and practical aspects.
Roelofs J, López-Gatius F, Hunter RH, van Eerdenburg FJ, Hanzen Ch. Roelofs J, et al. Among authors: hanzen ch. Theriogenology. 2010 Aug;74(3):327-44. doi: 10.1016/j.theriogenology.2010.02.016. Epub 2010 Apr 3. Theriogenology. 2010. PMID: 20363020 Review.
Impact of EGFRA289T/V mutation on relapse pattern in glioblastoma.
Noeuveglise A, Sarafan-Vasseur N, Beaussire L, Marguet F, Modzelewski R, Hanzen C, Alexandru C, Magne N, Langlois O, Di Fiore F, Clatot F, Thureau S, Fontanilles M. Noeuveglise A, et al. Among authors: hanzen c. ESMO Open. 2023 Feb;8(1):100740. doi: 10.1016/j.esmoop.2022.100740. Epub 2022 Dec 23. ESMO Open. 2023. PMID: 36566697 Free PMC article.
Postoperative irradiation for thyroid cancer.
Phlips P, Hanzen C, Andry G, Van Houtte P, Früuling J. Phlips P, et al. Among authors: hanzen c. Eur J Surg Oncol. 1993 Oct;19(5):399-404. Eur J Surg Oncol. 1993. PMID: 8405474
57 results